Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Is sexually active and has been in a steady relationship and plans to remain in that relationship for the duration of the study.~2. Has a body mass index (BMI) of 18 to 35 kg/m\^2, inclusive, at the Screening and Baseline Visits.~3. If female, has a regular menstrual cycle.~4. Has normal sexual functioning, as defined by a Changes in Sexual Functioning Questionnaire (CSFQ-14) total score \>47 (men) or \>41 (women) at the Screening and Baseline Visits.~5. If females, taking allowed hormonal contraceptives is on a stable dose for ≥3 months prior to the Baseline Visit and continues on the stable dose for the duration of the study.~Exclusion Criteria:~1. Has received vortioxetine and/or paroxetine in a previous clinical study or as a therapeutic agent.~2. Is positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) at the Screening Visit or has any known sexually transmitted diseases.~3. Has glycosylated hemoglobin (HbA1c) ≥7% at the Screening Visit.~4. Has a clinically significant abnormal electrocardiogram (ECG) at the Screening Visit.~5. Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.~6. Has a history of depression or any other psychiatric illness.~7. Has a significant risk of suicide according to the investigator's clinical judgment, or has made a suicide attempt in the previous 6 months.~8. Has current sexual dysfunction, or a history of a diagnosis or treatment of sexual dysfunction.~9. Has had a surgical or medical procedure on reproductive/genitourinary organs (excluding uncomplicated vasectomy and tubal ligation).~10. If female, has polycystic ovarian syndrome.~11. Has hypogonadism or has a free testosterone value outside the normal range at the Screening Visit that is indicative of hypogonadism.~12. Has a thyroid-stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Vortioxetine 10 mg (Type: EXPERIMENTAL): Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
- Vortioxetine 20 mg (Type: EXPERIMENTAL): Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
- Paroxetine 20 mg (Type: ACTIVE_COMPARATOR): Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).